Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats

Hu,Naiwu; Ren,Shujun; Li,Wei; Zhang,Tao; Zhao,Chengbin

doi:10.3892/mmr.2013.1399

Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats

Authors:
- Naiwu Hu
- Shujun Ren
- Wei Li
- Tao Zhang
- Chengbin Zhao
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Orthopedics and Traumatology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China
Published online on: March 28, 2013 https://doi.org/10.3892/mmr.2013.1399
Pages: 1565-1570

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the mechanism underlying the promotive effect of morroniside on rat mesenchymal stem cell (RMSC) proliferation and to provide an experimental basis for the development of potential new drugs. RMSCs were obtained from the bone marrow of Sprague-Dawley rats aged 3-4 months. The proliferation of primary and subcultured RMSCs in the high‑, medium‑ and low‑concentration morroniside intervention and blank control groups was observed using light microscopy. Cell proliferation and survival conditions were detected using methyl thiazolyl tetrazolium (MTT) colorimetric tests. Light microscopy and the MTT assay revealed that RMSC adherence time in the morroniside groups was shorter compared with that of the control group. Twelve hours after the media of primary RMSCs were changed, the number of adherent cells in the morroniside groups increased and an elongated cell morphology was observed. The cells at the fourth passage in the morroniside groups fused completely 12‑16 h after inoculation and then rapidly entered into the logarithmic phase. The primary RMSCs of the morroniside intervention groups grew into typical bone marrow mesenchymal stem cell (BMSC) colonies after 4 days of morroniside treatment and their fusion rate had reached 80% after 9‑11 days. By contrast, the cell fusion rate of the control group only reached 75-80% after 14 days of morroniside treatment. Morroniside exhibited a similar promotive effect on proliferation in primary and subcultured RMSCs. Morroniside may promote RMSC proliferation through secreted factors, cell-to-cell interactions and/or the interactions between cellular adhesion molecules and extracellular matrices (ECMs). However, the specific mechanism underlying this effect remains to be fully elucidated.

View Figures

View References

1	Bruder SP, Jaiswal N and Haynesworth SE: Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 64:278–294. 1997. View Article : Google Scholar
2	Long MW, Robinson JA, Ashcraft EA and Mann KG: Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest. 95:881–887. 1995. View Article : Google Scholar : PubMed/NCBI
3	Taguchi Y, Yamamoto M, Yamate T, et al: Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians. 110:559–574. 1998.PubMed/NCBI
4	Zhao K and Qin S: Bone tissue engineering research progress. J Liaoning Med Univ. 1:382–384. 2011.(In Chinese).
5	Carlo-Stella C and Gianni MA: Biology and clinical applications of marrow mesenchymal stem cells. Pathol Biol (Paris). 53:162–164. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kassem M: Mesenchymal stem cells: biological characteristics and potential clinical applications. Cloning Stem Cells. 6:369–374. 2004. View Article : Google Scholar : PubMed/NCBI
7	Okubo Y, Bessho K, Fujimura K, et al: Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int J Oral Maxillofac Surg. 29:62–66. 2000. View Article : Google Scholar : PubMed/NCBI
8	Inao M, Mochida S, Matsui A, et al: Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol. 41:584–591. 2004. View Article : Google Scholar : PubMed/NCBI
9	Hu Z, Zeng R, Guo W and Lin H: Induction and differentiation of bone marrow mesenchymal stem cells. J Clin Rehabil Tissue Eng Res. 12:8561–8566. 2008.(In Chinese).
10	Pontikoglou C, Deschaseaux F, Sensebé L and Papadaki HA: Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev. 7:569–589. 2011. View Article : Google Scholar : PubMed/NCBI
11	Xia W, Xu R, Ye X, et al: Biological appraisal of human bone marrow mesenchymal stem cells during ex-vivo expansion. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 16:639–644. 2008.(In Chinese).
12	Yoo HJ, Yoon SS, Park S, et al: Production and characterization of monoclonal antibodies to mesenchymal stem cells derived from human bone marrow. Hybndoma (Larchmt). 24:92–97. 2005. View Article : Google Scholar : PubMed/NCBI
13	Weinreb M, Grosskopf A and Shir N: The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol. 276:E376–E383. 1999.PubMed/NCBI
14	Kveiborg M, Flyvbjerg A, Eriksen EF and Kassem M: 1,25-Dihydroxyvitamin D3 stimulates the production of insulin-like growth-factor-binding proteins-2,-3 and -4 in human bone marrow stromal cells. Eur J Endocrinol. 144:549–557. 2001. View Article : Google Scholar : PubMed/NCBI
15	Tabin CJ: Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell. 66:199–217. 1991. View Article : Google Scholar : PubMed/NCBI
16	Gerhart TN, Kirker-Head CA, Kriz MJ, et al: Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Relat Res. 293:317–326. 1993.PubMed/NCBI
17	Locklin RM, Williamson MC, Beresford JN, Triffitt JT and Owen ME: In vitro effects of growth factors and dexamethasone on rat marrow stromal cells. Clin Orthop Relat Res. 313:27–35. 1995.PubMed/NCBI
18	Pungitore CR, Ayub MJ, García M, et al: Iridoids as allelochemicals and DNA polymerase inhibitors. J Nat Prod. 67:357–361. 2004. View Article : Google Scholar : PubMed/NCBI
19	Li YM, Li H and Li CR: Advance on chemical compositions and pharmacology of Cornus officinalis. Acta Academiae Medicinae CPAF. 6:74–75. 2010.
20	Wang W, Sun F and An Y: Morroniside inhibits hydrogen peroxide-induced calcium overload and cytotoxicity in SH-SY5Y neuroblastoma cells. Chin J Rehabil Theory Pract. 3:115–117. 2009.
21	Zhang L, Li C and Zhao L: Effects of cornel iridoid glycoside on nervous function and neuron damage in focal cerebral ischemic rats. Chin J Rehabil Theory Pract. 3:110–113. 2007.
22	Javazon EH, Colter DC, Schwarz EJ and Prockop DJ: Rat marow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells. Stem Cells. 19:219–225. 2001. View Article : Google Scholar : PubMed/NCBI
23	McCabe LR, Banerjee C, Kundu R, et al: Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology. 137:4398–4408. 1996.
24	Uludag H, D’Augusta D, Golden J, et al: Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: A correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res. 50:227–238. 2000. View Article : Google Scholar
25	Peng H, Wright V, Usas A, et al: Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest. 110:751–759. 2002. View Article : Google Scholar : PubMed/NCBI
26	Reddi AH: Bone morphogenetic proteins, bone marrow stromal cells, and mesenchymal stem cells. Maureen Owen revisited. Clin Orthop Relat Res. 313:115–119. 1995.PubMed/NCBI